You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer

    SBC: 7 Hills Pharma LLC            Topic: 102

    DESCRIPTION provided by applicant Recent FDA approvals of ipilimumab nivolumab and pembrolizumab which target checkpoint receptors cytotoxic T lymphocyte associated antigen CTLA and programmed death PD have ushered in a new era of cancer immunotherapy in metastatic melanoma Despite unprecedented overall survival benefits with combination therapy the incidence of complete respo ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Optimization of the Production and Isolation of the Novel Antifungal Occidiofungin

    SBC: Sano Chemicals, Inc.            Topic: NIAID

    DESCRIPTION provided by applicant Occidiofungin is a cyclic nonribosomally synthesized antifungal peptide with submicromolar fungicidal activity against a broad spectrum of fungi Occidiofungin is produced by the Gram negative bacterium Burkholderia contaminans From our structural characterization studies occidiofungin was determined to have a unique chemical composition Our studies have als ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Development of nucleic acid delivery platform based on polymeric CXCR4 antagonists

    SBC: Bohemica Pharmaceuticals, LLC            Topic: 100

    DESCRIPTION provided by applicant Therapeutics based on nucleic acids NA promise to revolutionize treatment of multiple diseases but their widespread use is currently limited by the lack of efficient delivery methods We have recently developed a new NA delivery platform based on polymeric CXCR inhibitors PCX suitable as dual function systems for simultaneous NA delivery and inhibition of ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Blood based diagnostics for Alzheimer s Disease

    SBC: Amprion, Inc.            Topic: NIA

    DESCRIPTION provided by applicant This proposal is for a phase I II fast track project for the STTR program with the main goal to develop a blood test for Alzheimerandapos s disease AD diagnosis AD is the most common dementia in the elderly population and one of the leading causes of death in the developed world One of the main problems in AD is the lack of an early sensitive and objective ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Monitored Breathing Awareness Therapy for Insomnia Disorder in Older Adults

    SBC: ADVANCED MEDICAL ELECTRONICS CORPORATION            Topic: NIA

    DESCRIPTION provided by applicant Insomnia of sufficient clinical severity to meet diagnostic criteria is present in approximately of older adults nearly million individuals n the US alone If left untreated it can lead to increased rates of depression cognitive impairment and cardiovascular disease Treatment relies on pharmacotherapy such as sedative hypnotic therapy which is ass ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Mutation Enriched Targeted Re Sequencing

    SBC: TRANSGENOMIC, INC.            Topic: 103

    DESCRIPTION provided by applicant Low level tumor associated somatic DNA mutations can have profound implications for development of metastasis prognosis choice of treatment follow up or early cancer detection Unless they are effectively detected these low level mutations can misinform patient management decisions or become missed opportunities for personalized medicine Widely used tech ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Digital Gene Expression Analysis by 3’ End Sequencing

    SBC: BIOO SCIENTIFIC CORPORATION            Topic: 172

    DESCRIPTION provided by applicant A key application of deep sequencing is gene expression analysis at the RNA level commonly known as RNA seq Reads from RNA seq cover all regions of an mRNA sequence However sequences derived from the andapos end region are sufficient to indicate gene expression levels All andapos end sequencing methods have revealed that most eukaryotic genes display a ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  8. Aptamers and BSI for Sub-Microliter Analysis of Pharmaceuticals in Neonatal Urine

    SBC: Base Pair Biotechnologies, Inc.            Topic: NICHD

    DESCRIPTION provided by applicant Neonatal and pediatric intensive care still involves performing painful needle punctures to obtain blood samples for routine clinical monitoring Pain management in the neonatal setting is often achieved by long term continuous intravenous infusion of morphine or related compounds It has become increasingly clear however that long term use of opioid compound ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. An eHealth solution for posttraumatic stress and pain screening integrated in pediatric injury care

    SBC: Radiant Creative Group, LLC            Topic: NICHD

    DESCRIPTION provided by applicant Each year million US children are injured affecting the child his her family and society which often bears the cost Among school age children age to injuries lead to million emergency department ED visits and hospital admissions annually resulting in $ billion in medical costs and $ billion more in work loss costs Approxima ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Optimized lactoferrin for treatment of intracerebral hemorrhage

    SBC: Pharmareview Corporation            Topic: 101

    DESCRIPTION provided by applicant Intracerebral hemorrhage ICH is a major public health problem with the highest mortality rate of all stroke subtypes ICH is one of the leading causes of long term disability Since there are no available FDA approved therapies for ICH it is of vast importance to search for new approaches in treatment for this devastating medical condition Lactoferrin LT ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government